RayKnowChina Research Map
Shortlist0

Taizhou (Jiangsu)Nanjing Medical University

Affiliated Taizhou People's Hospital of Nanjing Medical University

南京医科大学附属泰州人民医院

Listed for 8 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Affiliated Taizhou People's Hospital of Nanjing Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌7 papers led
  2. Hepatocellular carcinoma肝细胞癌18 papers led
  3. Stomach cancer胃癌15 papers led
  4. Osteosarcoma骨肉瘤2 papers led
  5. Ewing sarcoma尤文肉瘤1 paper led
  6. Wilson disease肝豆状核变性(Wilson 病)2 papers led
  7. Fabry disease法布雷病1 paper led
  8. IgA nephropathyIgA 肾病2 papers led

Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Neuroblastoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 7 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 1120242025: 332025

1 hospital in Taizhou (Jiangsu) for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05443841

    Age not stated (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 8 listed hospitals as study sitesHefei, Nantong, Shanghai, Shijiazhuang, Taizhou (Jiangsu), Tianjin, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesMolecular markers & genomicsRadiotherapyImaging & AI
Departments in papersMedical oncologyPathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led7
  1. Ginsenoside 20(S)-Rg3 Hinders Esophageal Squamous Cell Carcinoma Cells Malignant Behaviors by miR-210-3p/B4GALT5 Axis.2025Cell biochemistry and biophysics
  2. Radiation regulates the expression of HLA-I in esophageal squamous cell carcinoma through interferon-γ.2025Scientific reportsFree full text
  3. Improved circulating tumor DNA identification for detection of esophageal squamous cell carcinoma by enzymatic methyl sequencing and hybrid neural network.2025Scientific reportsFree full text
  4. Circ_0050444 represses esophageal squamous cell carcinoma progression through sponging miR-486-3p to upregulate C10orf91.2024Cell cycle (Georgetown, Tex.)Free full text
  5. Spectral CT - a new supplementary method for preoperative assessment of pathological grades of esophageal squamous cell carcinoma.2023BMC medical imagingFree full text
  6. High expression of guanine nucleotide-binding protein-like-3-like is associated with poor prognosis in esophageal cancer.2021MedicineFree full text
  7. Knockdown of long non-coding RNA CCAT2 suppresses growth and metastasis of esophageal squamous cell carcinoma by inhibiting the β-catenin/WISP1 signaling pathway.2021The Journal of international medical researchFree full text
Chinese-language papers (not in the count)1
  1. [Potential molecular mechanism of lncRNAs HOTAIR in malignant metastasis of esophageal cancer].2025Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
All its trials on ClinicalTrials.gov, any status2
  1. Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)RecruitingNCT05443841Study siteStart 2022-07
  2. Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 TrialStatus unknownNCT02319187Study sitePhase 3Start 2014-12
More papers found outside PubMed (not counted)5
  1. Real-world effectiveness and safety of first-line serplulimab in patients with metastatic or locally advanced esophageal carcinoma.2025Journal of Clinical Oncologyarticle
  2. Effectiveness and safety of first-line serplulimab in patients with metastatic/locally advanced esophageal carcinoma (EC): A real-world study.2024Journal of Clinical Oncologyconference-abstract
  3. Expression and correlation of Surfeit 4 gene in esophageal squamous cell carcinoma2024Holistic Integrative Oncologyarticle
  4. Preoperative Systemic Inflammatory Measures as a Maker of Recurrence in Patients with Early Esophageal Squamous Cell Cancer:a Cross-Sectional Retrospective Study2023Research Squarepreprint
  5. Postoperative Radiotherapy Involving Tumor Bed with or without Elective Nodal Irradiation in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center, Prospective Randomized Phase II Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 18 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
18
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 4420242025: 992025

1 hospital in Taizhou (Jiangsu) for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsHepatitis B & cirrhosis
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led18
  1. Tryptophan Suppresses FTH1-Driven Ferritinophagy, a Key Correlate of Prognosis in Hepatocellular Carcinoma.2026Cell proliferationFree full text
  2. Synergistic enhancement of ferroptosis via a multi-functional metal-coordinated nanoplatform for cancer therapy.2026Colloids and surfaces. B, Biointerfaces
  3. NSUN5 Facilitates Hepatocellular Carcinoma Progression by Increasing SMAD3 Expression.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. ASH2L-K312-Lac Stimulates Angiogenesis in Tumors to Expedite the Malignant Progression of Hepatocellular Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  5. Interaction between HBsAg response and the prognosis of patients with HBV-associated HCC receiving anti-PD-1/PD-L1.2025BMC infectious diseasesFree full text
  6. ABCF1-K430-Lactylation promotes HCC malignant progression via transcriptional activation of HIF1 signaling pathway.2025Cell death and differentiationFree full text
  7. mPEG-NH2/2-FPBA/TubA exerts anti-hepatocellular carcinoma activity by targeting ABCF1-K430la through the KDM3A-H3K9me2-HIF1A axis.2025Colloids and surfaces. B, Biointerfaces
  8. Baseline vitamin D status, genetic susceptibility, and the risk of incident hepatocellular carcinoma.2025International journal of cancer
  9. NUSAP1 Promotes Immunity and Apoptosis by the SHCBP1/JAK2/STAT3 Phosphorylation Pathway to Induce Dendritic Cell Generation in Hepatocellular Carcinoma.2025Journal of immunotherapy (Hagerstown, Md. : 1997)Free full text
  10. RBM30 recruits DOT1L to activate STAT1 transcription and drive immune evasion in hepatocellular carcinoma.2025Oncogene
  11. Combining AFP, PIVKA-II, and GP73 has diagnostic utility for hepatitis B-associated hepatocellular carcinoma and is consistent with liver pathology results.2025Scientific reportsFree full text
  12. Research Progress on Dendritic Cells in Hepatocellular Carcinoma Immune Microenvironments.2024BiomoleculesFree full text
  13. RNA-binding motif protein 28 enhances angiogenesis by improving STAT3 translation in hepatocellular carcinoma.2024Cancer letters
  14. Histone lactylation facilitates hepatocellular carcinoma progression by upregulating endothelial cell-specific molecule 1 expression.2024Molecular carcinogenesis
  15. RBM12 drives PD-L1-mediated immune evasion in hepatocellular carcinoma by increasing JAK1 mRNA translation.2024Oncogene
  16. RNA-binding motif 4 promotes angiogenesis in HCC by selectively activating VEGF-A expression.2023Pharmacological research
  17. N4BP3 promotes angiogenesis in hepatocellular carcinoma by binding with KAT2B.2022Cancer scienceFree full text
  18. Characteristics and accurate identification of Pantoea dispersa with a case of spontaneous rupture of hepatocellular carcinoma in China: A case report.2022MedicineFree full text
Chinese-language papers (not in the count)1
  1. [Limitations and cautions of a family history of HBV-related cirrhosis/hepatocellular carcinoma as a condition for initiating antiviral therapy in patients with HBV infection].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 15 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
15
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 3320232024: 1120242025: 662025

1 hospital in Taizhou (Jiangsu) for stomach cancer218 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseSurgeryImaging & AI
Departments in papersPathology / laboratory medicineGastroenterology / hepatologyMedical oncology

Over half of these papers are lab or animal studies.

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led15
  1. SUV39H1 Regulates Gastric Cancer Progression via the H3K9me3/ALDOB Axis.2025Cell biochemistry and biophysics
  2. Synergistic effects of dihydroartemisinin and cisplatin on inducing ferroptosis in gastric cancer through GPX4 inhibition.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  3. Unveiling potent bioactive compounds and anti-angiogenic pathways in Gekko swinhonis Guenther for gastric cancer therapy.2025Journal of ethnopharmacology
  4. piR-38,736 promotes gastric cancer cell proliferation by downregulating SMAD4 expression.2025Journal of molecular histologyFree full text
  5. Dihydroartemisinin inhibits galectin-1-induced ferroptosis resistance and peritoneal metastasis of gastric cancer via the Nrf2-HO-1 pathway.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  6. Association of preoperative body mass index with postoperative complications and survival for patients with gastric cancer: A systematic review and meta-analysis.2025PloS oneFree full text
  7. Dihydroartemisinin inhibited vasculogenic mimicry in gastric cancer through the FGF2/FGFR1 signaling pathway.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  8. Predicative factors and development of a nomogram for postoperative delayed neurocognitive recovery in elderly patients with gastric cancer.2023Aging clinical and experimental research
  9. Galectin-1 promotes gastric cancer peritoneal metastasis through peritoneal fibrosis.2023BMC cancerFree full text
  10. Association of genes in hereditary metabolic diseases with diagnosis, prognosis, and treatment outcomes in gastric cancer.2023Frontiers in immunologyFree full text
  11. Albumin/fibrinogen ratio, a predictor of chemotherapy resistance and prognostic factor for advanced gastric cancer patients following radical gastrectomy.2022BMC surgeryFree full text
  12. Risk factors and a nomogram model for postoperative delirium in elderly gastric cancer patients after laparoscopic gastrectomy.2022World journal of surgical oncologyFree full text
  13. Fibroblastic galectin-1-fostered invasion and metastasis are mediated by TGF-β1-induced epithelial-mesenchymal transition in gastric cancer.2021AgingFree full text
  14. LncRNA HEIH promotes cell proliferation, migration and invasion by suppressing miR-214-3p in gastric carcinoma.2021Journal of biochemistry
  15. FRA-1 suppresses apoptosis of Helicobacter pylori infected MGC-803 cells.2021Molecular biology reports
Chinese-language papers (not in the count)2
  1. [Comparison of the application of double tract anastomosis and single muscular flap valvuloplasty technique in laparoscopic proximal gastrectomy for digestive tract reconstruction].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Clinical study on transcutaneous electrical acupoint stimulation combined with skin sympathetic response to evaluate autonomic nerve preservation after laparoscopic radical gastrectomy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status1
  1. Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center StudyStatus unknownNCT03121729Study siteN/AStart 2017-06

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

1 hospital in Taizhou (Jiangsu) for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Taizhou (Jiangsu) for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led1
  1. TIPE1 inhibits the growth of Ewing's sarcoma cells by suppressing Wnt/β-catenin signaling.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led 2 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 1.0%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

1 hospital in Taizhou (Jiangsu) for Wilson disease28 hospitals in China for Wilson disease

No open trial on Wilson disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesGenetics (ATP7B)
Departments in papersNeurology

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led2
  1. Assessment of sleep disturbance in patients with Wilson's disease.2024BMC psychiatry
  2. Sleep disorders in Wilson's disease: a questionnaire study.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Taizhou (Jiangsu) for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Taizhou (Jiangsu) for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrologyPathology / laboratory medicine

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

南京医科大学附属泰州人民医院

Affiliated Taizhou People's Hospital of Nanjing Medical University

泰州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
TZPH; Taizhou People's Hospital; The Affiliated Taizhou People's Hospital of Nanjing Medical University

Suggest a correctionDownload the data